Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Intradermal, and Low-Dose Subcutaneous vs Subcutaneous Administration of Menomune- A/C/Y/W-135.

Next Previous
Trial Profile

Safety and Immunogenicity of Intradermal, and Low-Dose Subcutaneous vs Subcutaneous Administration of Menomune- A/C/Y/W-135.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2009

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi

Most Recent Events

  • 01 May 2009 Primary endpoints added as reported by ClinicalTrials.gov.
  • 26 Feb 2009 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top